Bukwang Pharmaceutical Co., Ltd. announced successful completion of a luncheon symposium for Lonasen Tab. (blonanserin) with the Korean College of Neuropsychopharmacology, held at Millennium Hilton Seoul.
Presentations at this symposium were about efficacy of monotherapy and safety of Lonasen with respect to treatment of early-stage schizophrenia. Professor Chan Hyeong Kim (Department of Psychiatry at Yonsei University) moderated the discussion, while Professor Young Min Park (Department of Psychiatry at Inje University) and Professor Jeong Seok Seo (Department of Psychiatry at Konkuk University) presented their talks.
According to their talks, Lonasen showed excellent efficacy given as monotherapy at 12~22mg doses in schizophrenia patients. Also Lonasen was shown to be safer than other medications for schizophrenia in that it is not associated with side effects such as hyperprolactinemia and weight gain.
Bukwang’s representative said, “Lonasen has cognitive improvement effects and low side effect rates, as well as improving patients’ positive symptoms. Therefore, we expect it to be welcomed by young schizophrenia patients with active social life.”
Lonasen Tab. is a medication for schizophrenia that contains blonanserin as its active therapeutic ingredient, developed by Sumitomo Dainippon of Japan and marketed in Korea by Bukwang Pharm. In addition to the preexisting 2mg and 4mg doses, 8mg formulation was newly launched in September 2015, further enhancing dosing convenience for the patients.